nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—CES2—Phase I biotransformations, non P450—PON1—brain cancer	0.0664	0.212	CbGpPWpGaD
Dabigatran etexilate—F2—vein—brain cancer	0.0404	0.166	CbGeAlD
Dabigatran etexilate—CES1—Phase I biotransformations, non P450—PON1—brain cancer	0.0391	0.125	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal ulcer—Hydroxyurea—brain cancer	0.0282	0.0634	CcSEcCtD
Dabigatran etexilate—Wound—Carmustine—brain cancer	0.0243	0.0547	CcSEcCtD
Dabigatran etexilate—UGT2B15—Tamoxifen metabolism—CYP2C9—brain cancer	0.0222	0.071	CbGpPWpGaD
Dabigatran etexilate—CES2—E2F transcription factor network—HIC1—brain cancer	0.0192	0.0614	CbGpPWpGaD
Dabigatran etexilate—F2—endothelium—brain cancer	0.0139	0.0571	CbGeAlD
Dabigatran etexilate—F2—blood vessel—brain cancer	0.0128	0.0527	CbGeAlD
Dabigatran etexilate—NQO2—hindbrain—brain cancer	0.0122	0.05	CbGeAlD
Dabigatran etexilate—CES1—E2F transcription factor network—HIC1—brain cancer	0.0113	0.0362	CbGpPWpGaD
Dabigatran etexilate—CES2—Irinotecan Pathway—APC—brain cancer	0.011	0.035	CbGpPWpGaD
Dabigatran etexilate—Contusion—Lomustine—brain cancer	0.0102	0.0229	CcSEcCtD
Dabigatran etexilate—UGT2B7—Tamoxifen metabolism—CYP2C9—brain cancer	0.0101	0.0323	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet Aggregation (Plug Formation)—MPL—brain cancer	0.00868	0.0277	CbGpPWpGaD
Dabigatran etexilate—Haemorrhage intracranial—Temozolomide—brain cancer	0.00829	0.0187	CcSEcCtD
Dabigatran etexilate—Epigastric discomfort—Hydroxyurea—brain cancer	0.00828	0.0187	CcSEcCtD
Dabigatran etexilate—Thrombosis—Procarbazine—brain cancer	0.00795	0.0179	CcSEcCtD
Dabigatran etexilate—Haemoptysis—Procarbazine—brain cancer	0.0076	0.0171	CcSEcCtD
Dabigatran etexilate—UGT2B15—endocrine gland—brain cancer	0.00715	0.0294	CbGeAlD
Dabigatran etexilate—NQO2—brainstem—brain cancer	0.00697	0.0287	CbGeAlD
Dabigatran etexilate—CES2—telencephalon—brain cancer	0.00693	0.0285	CbGeAlD
Dabigatran etexilate—CES1—Irinotecan Pathway—APC—brain cancer	0.00646	0.0206	CbGpPWpGaD
Dabigatran etexilate—Osteoarthritis—Lomustine—brain cancer	0.00643	0.0145	CcSEcCtD
Dabigatran etexilate—Cerebral haemorrhage—Carmustine—brain cancer	0.00636	0.0143	CcSEcCtD
Dabigatran etexilate—NQO2—telencephalon—brain cancer	0.00619	0.0254	CbGeAlD
Dabigatran etexilate—Cerebral haemorrhage—Temozolomide—brain cancer	0.00615	0.0138	CcSEcCtD
Dabigatran etexilate—UGT1A9—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.00587	0.0188	CbGpPWpGaD
Dabigatran etexilate—Transaminases increased—Carmustine—brain cancer	0.00579	0.013	CcSEcCtD
Dabigatran etexilate—CES2—gonad—brain cancer	0.00578	0.0238	CbGeAlD
Dabigatran etexilate—CES2—pituitary gland—brain cancer	0.00564	0.0232	CbGeAlD
Dabigatran etexilate—CES2—medulla oblongata—brain cancer	0.00544	0.0224	CbGeAlD
Dabigatran etexilate—UGT1A9—endocrine gland—brain cancer	0.00542	0.0223	CbGeAlD
Dabigatran etexilate—NQO2—pituitary gland—brain cancer	0.00504	0.0207	CbGeAlD
Dabigatran etexilate—CES2—midbrain—brain cancer	0.00497	0.0205	CbGeAlD
Dabigatran etexilate—Thrombosis—Carmustine—brain cancer	0.00497	0.0112	CcSEcCtD
Dabigatran etexilate—NQO2—medulla oblongata—brain cancer	0.00486	0.02	CbGeAlD
Dabigatran etexilate—CES2—spinal cord—brain cancer	0.00485	0.02	CbGeAlD
Dabigatran etexilate—Hepatic function abnormal—Procarbazine—brain cancer	0.00467	0.0105	CcSEcCtD
Dabigatran etexilate—Hepatic enzyme increased—Hydroxyurea—brain cancer	0.0046	0.0104	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Lomustine—brain cancer	0.00447	0.0101	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Lomustine—brain cancer	0.00445	0.01	CcSEcCtD
Dabigatran etexilate—NQO2—midbrain—brain cancer	0.00444	0.0183	CbGeAlD
Dabigatran etexilate—UGT2B7—endocrine gland—brain cancer	0.00437	0.018	CbGeAlD
Dabigatran etexilate—CES2—endocrine gland—brain cancer	0.00437	0.018	CbGeAlD
Dabigatran etexilate—F2—spinal cord—brain cancer	0.00435	0.0179	CbGeAlD
Dabigatran etexilate—NQO2—spinal cord—brain cancer	0.00434	0.0178	CbGeAlD
Dabigatran etexilate—CES2—head—brain cancer	0.00431	0.0177	CbGeAlD
Dabigatran etexilate—UGT2B15—Biological oxidations—CYP2C9—brain cancer	0.00413	0.0132	CbGpPWpGaD
Dabigatran etexilate—CES2—E2F transcription factor network—SIRT1—brain cancer	0.00411	0.0131	CbGpPWpGaD
Dabigatran etexilate—CES2—E2F transcription factor network—CCNE1—brain cancer	0.00406	0.013	CbGpPWpGaD
Dabigatran etexilate—CES2—central nervous system—brain cancer	0.00394	0.0162	CbGeAlD
Dabigatran etexilate—F2—endocrine gland—brain cancer	0.00392	0.0161	CbGeAlD
Dabigatran etexilate—NQO2—endocrine gland—brain cancer	0.0039	0.0161	CbGeAlD
Dabigatran etexilate—F2—head—brain cancer	0.00387	0.0159	CbGeAlD
Dabigatran etexilate—NQO2—head—brain cancer	0.00385	0.0158	CbGeAlD
Dabigatran etexilate—CES2—cerebellum—brain cancer	0.00385	0.0158	CbGeAlD
Dabigatran etexilate—Hyperbilirubinaemia—Temozolomide—brain cancer	0.00374	0.00843	CcSEcCtD
Dabigatran etexilate—CES1—endocrine gland—brain cancer	0.0036	0.0148	CbGeAlD
Dabigatran etexilate—Hepatic enzyme increased—Temozolomide—brain cancer	0.0036	0.0081	CcSEcCtD
Dabigatran etexilate—Infection—Carboplatin—brain cancer	0.00359	0.00809	CcSEcCtD
Dabigatran etexilate—CES1—head—brain cancer	0.00355	0.0146	CbGeAlD
Dabigatran etexilate—F2—central nervous system—brain cancer	0.00353	0.0145	CbGeAlD
Dabigatran etexilate—Dysphagia—Procarbazine—brain cancer	0.00353	0.00795	CcSEcCtD
Dabigatran etexilate—NQO2—central nervous system—brain cancer	0.00352	0.0145	CbGeAlD
Dabigatran etexilate—Musculoskeletal pain—Temozolomide—brain cancer	0.00344	0.00776	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Procarbazine—brain cancer	0.00344	0.00775	CcSEcCtD
Dabigatran etexilate—NQO2—cerebellum—brain cancer	0.00344	0.0141	CbGeAlD
Dabigatran etexilate—F2—PAR1-mediated thrombin signaling events—TRPC6—brain cancer	0.00341	0.0109	CbGpPWpGaD
Dabigatran etexilate—CES1—central nervous system—brain cancer	0.00324	0.0133	CbGeAlD
Dabigatran etexilate—Pneumonia—Procarbazine—brain cancer	0.00317	0.00713	CcSEcCtD
Dabigatran etexilate—Infection—Lomustine—brain cancer	0.00314	0.00708	CcSEcCtD
Dabigatran etexilate—CES2—brain—brain cancer	0.00313	0.0129	CbGeAlD
Dabigatran etexilate—Thrombocytopenia—Lomustine—brain cancer	0.0031	0.00698	CcSEcCtD
Dabigatran etexilate—Chest discomfort—Etoposide—brain cancer	0.00308	0.00693	CcSEcCtD
Dabigatran etexilate—UGT1A9—Irinotecan Pathway—APC—brain cancer	0.00302	0.00964	CbGpPWpGaD
Dabigatran etexilate—Haematuria—Procarbazine—brain cancer	0.003	0.00676	CcSEcCtD
Dabigatran etexilate—Epistaxis—Procarbazine—brain cancer	0.00297	0.00669	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Procarbazine—brain cancer	0.00284	0.0064	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Procarbazine—brain cancer	0.00283	0.00637	CcSEcCtD
Dabigatran etexilate—F2—brain—brain cancer	0.0028	0.0115	CbGeAlD
Dabigatran etexilate—NQO2—brain—brain cancer	0.00279	0.0115	CbGeAlD
Dabigatran etexilate—ABCB1—blood vessel—brain cancer	0.00275	0.0113	CbGeAlD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—PPP1R12A—brain cancer	0.00273	0.00873	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.00269	0.00861	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—BSG—brain cancer	0.00267	0.00853	CbGpPWpGaD
Dabigatran etexilate—CES1—brain—brain cancer	0.00257	0.0106	CbGeAlD
Dabigatran etexilate—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.00257	0.0082	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal haemorrhage—Carmustine—brain cancer	0.00256	0.00576	CcSEcCtD
Dabigatran etexilate—CES2—Fluoropyrimidine Activity—TP53—brain cancer	0.00249	0.00797	CbGpPWpGaD
Dabigatran etexilate—Oesophagitis—Etoposide—brain cancer	0.00249	0.0056	CcSEcCtD
Dabigatran etexilate—Infestation—Hydroxyurea—brain cancer	0.00244	0.00549	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Hydroxyurea—brain cancer	0.00244	0.00549	CcSEcCtD
Dabigatran etexilate—CES1—E2F transcription factor network—SIRT1—brain cancer	0.00242	0.00774	CbGpPWpGaD
Dabigatran etexilate—CES1—E2F transcription factor network—CCNE1—brain cancer	0.00239	0.00764	CbGpPWpGaD
Dabigatran etexilate—CES2—E2F transcription factor network—CDKN2A—brain cancer	0.00237	0.00759	CbGpPWpGaD
Dabigatran etexilate—Liver function test abnormal—Carmustine—brain cancer	0.00236	0.00532	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Hydroxyurea—brain cancer	0.0023	0.00519	CcSEcCtD
Dabigatran etexilate—Anaemia—Procarbazine—brain cancer	0.00227	0.00512	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Temozolomide—brain cancer	0.00222	0.00501	CcSEcCtD
Dabigatran etexilate—Dysphagia—Carmustine—brain cancer	0.00221	0.00498	CcSEcCtD
Dabigatran etexilate—Syncope—Procarbazine—brain cancer	0.00221	0.00497	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Hydroxyurea—brain cancer	0.0022	0.00495	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Hydroxyurea—brain cancer	0.00219	0.00493	CcSEcCtD
Dabigatran etexilate—Cardiac failure congestive—Etoposide—brain cancer	0.00218	0.00491	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Temozolomide—brain cancer	0.00218	0.00491	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Procarbazine—brain cancer	0.00216	0.00487	CcSEcCtD
Dabigatran etexilate—Cough—Procarbazine—brain cancer	0.00215	0.00484	CcSEcCtD
Dabigatran etexilate—Dysphagia—Temozolomide—brain cancer	0.00213	0.00481	CcSEcCtD
Dabigatran etexilate—Hypertension—Procarbazine—brain cancer	0.00212	0.00478	CcSEcCtD
Dabigatran etexilate—Arthralgia—Procarbazine—brain cancer	0.00209	0.00472	CcSEcCtD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—MPL—brain cancer	0.00208	0.00664	CbGpPWpGaD
Dabigatran etexilate—Bronchitis—Temozolomide—brain cancer	0.00205	0.00462	CcSEcCtD
Dabigatran etexilate—Cardiac failure—Etoposide—brain cancer	0.00203	0.00456	CcSEcCtD
Dabigatran etexilate—Vomiting—Lomustine—brain cancer	0.00201	0.00453	CcSEcCtD
Dabigatran etexilate—Infection—Procarbazine—brain cancer	0.00199	0.00449	CcSEcCtD
Dabigatran etexilate—Angiopathy—Hydroxyurea—brain cancer	0.00198	0.00447	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Temozolomide—brain cancer	0.00198	0.00447	CcSEcCtD
Dabigatran etexilate—Pneumonia—Carmustine—brain cancer	0.00198	0.00446	CcSEcCtD
Dabigatran etexilate—Shock—Procarbazine—brain cancer	0.00198	0.00445	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Procarbazine—brain cancer	0.00197	0.00443	CcSEcCtD
Dabigatran etexilate—UGT1A9—PPAR Alpha Pathway—CDK4—brain cancer	0.00195	0.00624	CbGpPWpGaD
Dabigatran etexilate—Urinary tract infection—Carmustine—brain cancer	0.00191	0.00431	CcSEcCtD
Dabigatran etexilate—Pneumonia—Temozolomide—brain cancer	0.00191	0.00431	CcSEcCtD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—SOD2—brain cancer	0.00191	0.00611	CbGpPWpGaD
Dabigatran etexilate—Infestation NOS—Temozolomide—brain cancer	0.0019	0.00429	CcSEcCtD
Dabigatran etexilate—Infestation—Temozolomide—brain cancer	0.0019	0.00429	CcSEcCtD
Dabigatran etexilate—UGT2B7—Biological oxidations—CYP2C9—brain cancer	0.00188	0.00601	CbGpPWpGaD
Dabigatran etexilate—Nausea—Lomustine—brain cancer	0.00188	0.00423	CcSEcCtD
Dabigatran etexilate—Hypotension—Procarbazine—brain cancer	0.00188	0.00423	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metapathway biotransformation—CYP2C9—brain cancer	0.00186	0.00593	CbGpPWpGaD
Dabigatran etexilate—Urinary tract infection—Temozolomide—brain cancer	0.00185	0.00417	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Procarbazine—brain cancer	0.00183	0.00412	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Temozolomide—brain cancer	0.0018	0.00406	CcSEcCtD
Dabigatran etexilate—Sinusitis—Temozolomide—brain cancer	0.00179	0.00402	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Carmustine—brain cancer	0.00178	0.004	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Carmustine—brain cancer	0.00177	0.00398	CcSEcCtD
Dabigatran etexilate—Anaemia—Hydroxyurea—brain cancer	0.00176	0.00396	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Etoposide—brain cancer	0.00174	0.00393	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Carmustine—brain cancer	0.00174	0.00392	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Carmustine—brain cancer	0.00174	0.00391	CcSEcCtD
Dabigatran etexilate—Fatigue—Procarbazine—brain cancer	0.00173	0.0039	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Temozolomide—brain cancer	0.00172	0.00387	CcSEcCtD
Dabigatran etexilate—Constipation—Procarbazine—brain cancer	0.00172	0.00387	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Temozolomide—brain cancer	0.00171	0.00385	CcSEcCtD
Dabigatran etexilate—Dysphagia—Etoposide—brain cancer	0.00171	0.00385	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Temozolomide—brain cancer	0.00169	0.0038	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Temozolomide—brain cancer	0.00168	0.00379	CcSEcCtD
Dabigatran etexilate—Bronchospasm—Etoposide—brain cancer	0.00168	0.00379	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Temozolomide—brain cancer	0.00168	0.00378	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Temozolomide—brain cancer	0.00167	0.00377	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Procarbazine—brain cancer	0.00164	0.0037	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.00161	0.00363	CcSEcCtD
Dabigatran etexilate—CES2—E2F transcription factor network—MYC—brain cancer	0.00161	0.00514	CbGpPWpGaD
Dabigatran etexilate—Urticaria—Procarbazine—brain cancer	0.0016	0.00359	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Procarbazine—brain cancer	0.00159	0.00358	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Temozolomide—brain cancer	0.00159	0.00357	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—HES1—brain cancer	0.00158	0.00504	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—SOD2—brain cancer	0.00156	0.00497	CbGpPWpGaD
Dabigatran etexilate—Angiopathy—Temozolomide—brain cancer	0.00155	0.00349	CcSEcCtD
Dabigatran etexilate—Infection—Hydroxyurea—brain cancer	0.00154	0.00348	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Temozolomide—brain cancer	0.00154	0.00348	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Temozolomide—brain cancer	0.00154	0.00347	CcSEcCtD
Dabigatran etexilate—Malnutrition—Carmustine—brain cancer	0.00154	0.00347	CcSEcCtD
Dabigatran etexilate—Pneumonia—Etoposide—brain cancer	0.00153	0.00345	CcSEcCtD
Dabigatran etexilate—UGT1A9—Biological oxidations—CYP2C9—brain cancer	0.00153	0.00489	CbGpPWpGaD
Dabigatran etexilate—Nervous system disorder—Hydroxyurea—brain cancer	0.00152	0.00343	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Etoposide—brain cancer	0.00152	0.00343	CcSEcCtD
Dabigatran etexilate—Infestation—Etoposide—brain cancer	0.00152	0.00343	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Hydroxyurea—brain cancer	0.00152	0.00343	CcSEcCtD
Dabigatran etexilate—Skin disorder—Hydroxyurea—brain cancer	0.00151	0.0034	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—CYP2C9—brain cancer	0.00151	0.00482	CbGpPWpGaD
Dabigatran etexilate—Acute coronary syndrome—Etoposide—brain cancer	0.0015	0.00338	CcSEcCtD
Dabigatran etexilate—Myocardial infarction—Etoposide—brain cancer	0.00149	0.00336	CcSEcCtD
Dabigatran etexilate—Back pain—Carmustine—brain cancer	0.00149	0.00335	CcSEcCtD
Dabigatran etexilate—Malnutrition—Temozolomide—brain cancer	0.00149	0.00335	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Procarbazine—brain cancer	0.00148	0.00333	CcSEcCtD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—TP53—brain cancer	0.00147	0.0047	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Procarbazine—brain cancer	0.00144	0.00325	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Etoposide—brain cancer	0.00144	0.00324	CcSEcCtD
Dabigatran etexilate—Back pain—Temozolomide—brain cancer	0.00144	0.00324	CcSEcCtD
Dabigatran etexilate—Anaemia—Carmustine—brain cancer	0.00142	0.0032	CcSEcCtD
Dabigatran etexilate—Pruritus—Procarbazine—brain cancer	0.00142	0.0032	CcSEcCtD
Dabigatran etexilate—CES1—E2F transcription factor network—CDKN2A—brain cancer	0.0014	0.00447	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Hydroxyurea—brain cancer	0.00139	0.00312	CcSEcCtD
Dabigatran etexilate—Anaemia—Temozolomide—brain cancer	0.00137	0.0031	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Procarbazine—brain cancer	0.00137	0.00309	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Hydroxyurea—brain cancer	0.00137	0.00308	CcSEcCtD
Dabigatran etexilate—Angioedema—Temozolomide—brain cancer	0.00136	0.00306	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Etoposide—brain cancer	0.00135	0.00304	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.00134	0.00302	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Etoposide—brain cancer	0.00134	0.00302	CcSEcCtD
Dabigatran etexilate—Fatigue—Hydroxyurea—brain cancer	0.00134	0.00302	CcSEcCtD
Dabigatran etexilate—ABCB1—telencephalon—brain cancer	0.00134	0.00549	CbGeAlD
Dabigatran etexilate—Hypertension—Carmustine—brain cancer	0.00133	0.00299	CcSEcCtD
Dabigatran etexilate—Constipation—Hydroxyurea—brain cancer	0.00133	0.00299	CcSEcCtD
Dabigatran etexilate—Dizziness—Procarbazine—brain cancer	0.00133	0.00299	CcSEcCtD
Dabigatran etexilate—Palpitations—Temozolomide—brain cancer	0.00131	0.00296	CcSEcCtD
Dabigatran etexilate—Chest pain—Carmustine—brain cancer	0.00131	0.00295	CcSEcCtD
Dabigatran etexilate—Cough—Temozolomide—brain cancer	0.0013	0.00292	CcSEcCtD
Dabigatran etexilate—Hypertension—Temozolomide—brain cancer	0.00128	0.00289	CcSEcCtD
Dabigatran etexilate—Vomiting—Procarbazine—brain cancer	0.00128	0.00288	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Etoposide—brain cancer	0.00127	0.00286	CcSEcCtD
Dabigatran etexilate—Arthralgia—Temozolomide—brain cancer	0.00127	0.00285	CcSEcCtD
Dabigatran etexilate—Rash—Procarbazine—brain cancer	0.00127	0.00285	CcSEcCtD
Dabigatran etexilate—Dermatitis—Procarbazine—brain cancer	0.00126	0.00285	CcSEcCtD
Dabigatran etexilate—UGT1A9—PPAR Alpha Pathway—CCND1—brain cancer	0.00126	0.00403	CbGpPWpGaD
Dabigatran etexilate—Headache—Procarbazine—brain cancer	0.00126	0.00283	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.00126	0.00283	CcSEcCtD
Dabigatran etexilate—Infection—Carmustine—brain cancer	0.00125	0.00281	CcSEcCtD
Dabigatran etexilate—Angiopathy—Etoposide—brain cancer	0.00124	0.00279	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—SOD2—brain cancer	0.00124	0.00395	CbGpPWpGaD
Dabigatran etexilate—Immune system disorder—Etoposide—brain cancer	0.00123	0.00278	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Etoposide—brain cancer	0.00123	0.00278	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Carmustine—brain cancer	0.00123	0.00277	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Temozolomide—brain cancer	0.00121	0.00273	CcSEcCtD
Dabigatran etexilate—Infection—Temozolomide—brain cancer	0.00121	0.00272	CcSEcCtD
Dabigatran etexilate—Nausea—Procarbazine—brain cancer	0.00119	0.00269	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Temozolomide—brain cancer	0.00119	0.00268	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Temozolomide—brain cancer	0.00119	0.00268	CcSEcCtD
Dabigatran etexilate—Skin disorder—Temozolomide—brain cancer	0.00118	0.00266	CcSEcCtD
Dabigatran etexilate—Hypotension—Carmustine—brain cancer	0.00117	0.00264	CcSEcCtD
Dabigatran etexilate—Back pain—Etoposide—brain cancer	0.00115	0.00259	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Hydroxyurea—brain cancer	0.00114	0.00258	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Carmustine—brain cancer	0.00114	0.00258	CcSEcCtD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—RELA—brain cancer	0.00112	0.00359	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Carmustine—brain cancer	0.00112	0.00252	CcSEcCtD
Dabigatran etexilate—ABCB1—gonad—brain cancer	0.00112	0.00458	CbGeAlD
Dabigatran etexilate—Asthenia—Hydroxyurea—brain cancer	0.00111	0.00251	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Temozolomide—brain cancer	0.00111	0.00249	CcSEcCtD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—RELA—brain cancer	0.00111	0.00353	CbGpPWpGaD
Dabigatran etexilate—Anaemia—Etoposide—brain cancer	0.0011	0.00248	CcSEcCtD
Dabigatran etexilate—ABCB1—pituitary gland—brain cancer	0.00109	0.00447	CbGeAlD
Dabigatran etexilate—Gastrointestinal disorder—Carmustine—brain cancer	0.00108	0.00244	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Temozolomide—brain cancer	0.00108	0.00244	CcSEcCtD
Dabigatran etexilate—Constipation—Carmustine—brain cancer	0.00107	0.00242	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—MPL—brain cancer	0.00107	0.00342	CbGpPWpGaD
Dabigatran etexilate—Dyspepsia—Temozolomide—brain cancer	0.00107	0.00241	CcSEcCtD
Dabigatran etexilate—F2—GPCR ligand binding—PTCH2—brain cancer	0.00107	0.00341	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Hydroxyurea—brain cancer	0.00106	0.0024	CcSEcCtD
Dabigatran etexilate—F2—G alpha (q) signalling events—TRPC6—brain cancer	0.00105	0.00336	CbGpPWpGaD
Dabigatran etexilate—ABCB1—medulla oblongata—brain cancer	0.00105	0.00432	CbGeAlD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—SKP2—brain cancer	0.00105	0.00335	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal disorder—Temozolomide—brain cancer	0.00105	0.00236	CcSEcCtD
Dabigatran etexilate—Fatigue—Temozolomide—brain cancer	0.00105	0.00236	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Etoposide—brain cancer	0.00105	0.00236	CcSEcCtD
Dabigatran etexilate—Cough—Etoposide—brain cancer	0.00104	0.00234	CcSEcCtD
Dabigatran etexilate—Constipation—Temozolomide—brain cancer	0.00104	0.00234	CcSEcCtD
Dabigatran etexilate—Hypertension—Etoposide—brain cancer	0.00103	0.00231	CcSEcCtD
Dabigatran etexilate—Dizziness—Hydroxyurea—brain cancer	0.00103	0.00231	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Carmustine—brain cancer	0.00103	0.00231	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—S100A10—brain cancer	0.00103	0.00328	CbGpPWpGaD
Dabigatran etexilate—Chest pain—Etoposide—brain cancer	0.00101	0.00228	CcSEcCtD
Dabigatran etexilate—UGT1A9—PPAR Alpha Pathway—MYC—brain cancer	0.00101	0.00323	CbGpPWpGaD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.00101	0.00227	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Carmustine—brain cancer	0.000993	0.00224	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Temozolomide—brain cancer	0.000993	0.00224	CcSEcCtD
Dabigatran etexilate—Vomiting—Hydroxyurea—brain cancer	0.000988	0.00223	CcSEcCtD
Dabigatran etexilate—Rash—Hydroxyurea—brain cancer	0.00098	0.00221	CcSEcCtD
Dabigatran etexilate—Dermatitis—Hydroxyurea—brain cancer	0.000979	0.00221	CcSEcCtD
Dabigatran etexilate—Headache—Hydroxyurea—brain cancer	0.000973	0.00219	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Etoposide—brain cancer	0.000971	0.00219	CcSEcCtD
Dabigatran etexilate—Infection—Etoposide—brain cancer	0.000965	0.00217	CcSEcCtD
Dabigatran etexilate—Urticaria—Temozolomide—brain cancer	0.000964	0.00217	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Temozolomide—brain cancer	0.00096	0.00216	CcSEcCtD
Dabigatran etexilate—ABCB1—midbrain—brain cancer	0.000959	0.00394	CbGeAlD
Dabigatran etexilate—Thrombocytopenia—Etoposide—brain cancer	0.000951	0.00214	CcSEcCtD
Dabigatran etexilate—CES1—E2F transcription factor network—MYC—brain cancer	0.000949	0.00303	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—VAV1—brain cancer	0.000945	0.00302	CbGpPWpGaD
Dabigatran etexilate—Skin disorder—Etoposide—brain cancer	0.000944	0.00213	CcSEcCtD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—brain cancer	0.00094	0.00301	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—OR4C12—brain cancer	0.000936	0.00299	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—OR14C36—brain cancer	0.000936	0.00299	CbGpPWpGaD
Dabigatran etexilate—ABCB1—spinal cord—brain cancer	0.000936	0.00385	CbGeAlD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDK6—brain cancer	0.000935	0.00299	CbGpPWpGaD
Dabigatran etexilate—Hypersensitivity—Carmustine—brain cancer	0.000925	0.00208	CcSEcCtD
Dabigatran etexilate—Nausea—Hydroxyurea—brain cancer	0.000923	0.00208	CcSEcCtD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—TRPC6—brain cancer	0.00092	0.00294	CbGpPWpGaD
Dabigatran etexilate—Hypotension—Etoposide—brain cancer	0.000908	0.00204	CcSEcCtD
Dabigatran etexilate—Asthenia—Carmustine—brain cancer	0.000901	0.00203	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—RELA—brain cancer	0.000899	0.00287	CbGpPWpGaD
Dabigatran etexilate—Hypersensitivity—Temozolomide—brain cancer	0.000894	0.00201	CcSEcCtD
Dabigatran etexilate—Asthenia—Temozolomide—brain cancer	0.000871	0.00196	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Etoposide—brain cancer	0.000866	0.00195	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Carmustine—brain cancer	0.000859	0.00194	CcSEcCtD
Dabigatran etexilate—Pruritus—Temozolomide—brain cancer	0.000859	0.00193	CcSEcCtD
Dabigatran etexilate—F2—Signaling by GPCR—OR14C36—brain cancer	0.00085	0.00272	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—OR4C12—brain cancer	0.00085	0.00272	CbGpPWpGaD
Dabigatran etexilate—ABCB1—endocrine gland—brain cancer	0.000843	0.00346	CbGeAlD
Dabigatran etexilate—Gastrointestinal disorder—Etoposide—brain cancer	0.000839	0.00189	CcSEcCtD
Dabigatran etexilate—Fatigue—Etoposide—brain cancer	0.000837	0.00189	CcSEcCtD
Dabigatran etexilate—ABCB1—head—brain cancer	0.000832	0.00342	CbGeAlD
Dabigatran etexilate—Dizziness—Carmustine—brain cancer	0.000831	0.00187	CcSEcCtD
Dabigatran etexilate—Constipation—Etoposide—brain cancer	0.000831	0.00187	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Temozolomide—brain cancer	0.000831	0.00187	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—brain cancer	0.000819	0.00262	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—IL2—brain cancer	0.00081	0.00259	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Temozolomide—brain cancer	0.000803	0.00181	CcSEcCtD
Dabigatran etexilate—Vomiting—Carmustine—brain cancer	0.000799	0.0018	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Etoposide—brain cancer	0.000794	0.00179	CcSEcCtD
Dabigatran etexilate—Rash—Carmustine—brain cancer	0.000792	0.00178	CcSEcCtD
Dabigatran etexilate—Dermatitis—Carmustine—brain cancer	0.000791	0.00178	CcSEcCtD
Dabigatran etexilate—Headache—Carmustine—brain cancer	0.000787	0.00177	CcSEcCtD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—PDGFRA—brain cancer	0.000774	0.00247	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Temozolomide—brain cancer	0.000772	0.00174	CcSEcCtD
Dabigatran etexilate—Urticaria—Etoposide—brain cancer	0.000772	0.00174	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Etoposide—brain cancer	0.000768	0.00173	CcSEcCtD
Dabigatran etexilate—Rash—Temozolomide—brain cancer	0.000765	0.00172	CcSEcCtD
Dabigatran etexilate—Dermatitis—Temozolomide—brain cancer	0.000765	0.00172	CcSEcCtD
Dabigatran etexilate—Headache—Temozolomide—brain cancer	0.00076	0.00171	CcSEcCtD
Dabigatran etexilate—ABCB1—central nervous system—brain cancer	0.000759	0.00312	CbGeAlD
Dabigatran etexilate—Nausea—Carmustine—brain cancer	0.000746	0.00168	CcSEcCtD
Dabigatran etexilate—ABCB1—cerebellum—brain cancer	0.000742	0.00305	CbGeAlD
Dabigatran etexilate—F2—Hemostasis—BSG—brain cancer	0.000723	0.00231	CbGpPWpGaD
Dabigatran etexilate—Nausea—Temozolomide—brain cancer	0.000721	0.00162	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Etoposide—brain cancer	0.000716	0.00161	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—RELA—brain cancer	0.000714	0.00228	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CYP2C9—brain cancer	0.000706	0.00226	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Etoposide—brain cancer	0.000697	0.00157	CcSEcCtD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—VAV1—brain cancer	0.000689	0.0022	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Etoposide—brain cancer	0.000687	0.00155	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Etoposide—brain cancer	0.000665	0.0015	CcSEcCtD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—brain cancer	0.000655	0.00209	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Etoposide—brain cancer	0.000642	0.00145	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	0.000627	0.002	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Etoposide—brain cancer	0.000618	0.00139	CcSEcCtD
Dabigatran etexilate—Rash—Etoposide—brain cancer	0.000612	0.00138	CcSEcCtD
Dabigatran etexilate—Dermatitis—Etoposide—brain cancer	0.000612	0.00138	CcSEcCtD
Dabigatran etexilate—Headache—Etoposide—brain cancer	0.000609	0.00137	CcSEcCtD
Dabigatran etexilate—ABCB1—brain—brain cancer	0.000603	0.00248	CbGeAlD
Dabigatran etexilate—UGT2B15—Metabolism—BSG—brain cancer	0.000601	0.00192	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—PIK3CG—brain cancer	0.0006	0.00192	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—APC—brain cancer	0.0006	0.00192	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	0.000587	0.00188	CbGpPWpGaD
Dabigatran etexilate—Nausea—Etoposide—brain cancer	0.000577	0.0013	CcSEcCtD
Dabigatran etexilate—F2—GPCR ligand binding—SHH—brain cancer	0.00055	0.00176	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PTCH2—brain cancer	0.000548	0.00175	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—SMO—brain cancer	0.000521	0.00167	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—PTCH1—brain cancer	0.000521	0.00167	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—TP53—brain cancer	0.00052	0.00166	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—IDH1—brain cancer	0.000516	0.00165	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—OR4C12—brain cancer	0.000502	0.00161	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—OR14C36—brain cancer	0.000502	0.00161	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TRPC6—brain cancer	0.000474	0.00152	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—ABR—brain cancer	0.000473	0.00151	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—PDGFRA—brain cancer	0.000447	0.00143	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—PIK3CG—brain cancer	0.000438	0.0014	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—ABR—brain cancer	0.00043	0.00137	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—IDH1—brain cancer	0.000429	0.00137	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—DTX2—brain cancer	0.000427	0.00136	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ENO2—brain cancer	0.000408	0.0013	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—brain cancer	0.000373	0.00119	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—VAV1—brain cancer	0.000355	0.00114	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—brain cancer	0.000353	0.00113	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTCH2—brain cancer	0.000324	0.00103	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—EGFR—brain cancer	0.000323	0.00103	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYP2C9—brain cancer	0.000322	0.00103	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HES5—brain cancer	0.000313	0.001	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—S100A10—brain cancer	0.000309	0.000988	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—IL2—brain cancer	0.000308	0.000984	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—STRADA—brain cancer	0.000304	0.000972	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—TRPC6—brain cancer	0.0003	0.000958	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—brain cancer	0.000298	0.000953	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—SHH—brain cancer	0.000282	0.000902	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—brain cancer	0.000279	0.000893	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—BSG—brain cancer	0.000274	0.000874	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—TRPC6—brain cancer	0.000272	0.00087	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—SMO—brain cancer	0.000268	0.000855	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PTCH1—brain cancer	0.000268	0.000855	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—VEGFA—brain cancer	0.000262	0.000836	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP2C9—brain cancer	0.000261	0.000836	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ABR—brain cancer	0.000254	0.000812	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GLI2—brain cancer	0.000245	0.000784	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—brain cancer	0.000245	0.000783	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL2—brain cancer	0.000244	0.000779	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—brain cancer	0.000241	0.00077	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—SIRT1—brain cancer	0.00024	0.000768	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—VEGFA—brain cancer	0.000239	0.000765	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—brain cancer	0.000237	0.000758	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—IDH1—brain cancer	0.000235	0.000752	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GLI1—brain cancer	0.000231	0.000737	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CG—brain cancer	0.000226	0.000721	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—VAV1—brain cancer	0.000225	0.000718	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—BSG—brain cancer	0.000222	0.00071	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—brain cancer	0.000221	0.000705	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SUFU—brain cancer	0.000219	0.000699	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GFAP—brain cancer	0.000211	0.000674	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—brain cancer	0.00021	0.000672	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—VEGFA—brain cancer	0.000207	0.000662	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—VAV1—brain cancer	0.000204	0.000652	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HEY1—brain cancer	0.0002	0.000639	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—DLL1—brain cancer	0.000196	0.000627	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—IDH1—brain cancer	0.000191	0.000611	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CG—brain cancer	0.000187	0.000599	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ENO2—brain cancer	0.000186	0.000594	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	0.000182	0.000581	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—APC—brain cancer	0.000171	0.000546	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SHH—brain cancer	0.000167	0.000533	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TRPC6—brain cancer	0.000161	0.000514	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IL2—brain cancer	0.000159	0.000507	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTCH1—brain cancer	0.000158	0.000505	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SMO—brain cancer	0.000158	0.000505	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	0.000156	0.000497	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ENO2—brain cancer	0.000151	0.000483	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—TRPC6—brain cancer	0.000143	0.000456	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CG—brain cancer	0.000143	0.000456	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—VEGFA—brain cancer	0.000135	0.000431	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	0.000133	0.000424	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CG—brain cancer	0.000129	0.000414	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NOTCH2—brain cancer	0.000126	0.000404	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CTNNB1—brain cancer	0.000121	0.000385	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VAV1—brain cancer	0.00012	0.000385	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP2C9—brain cancer	0.00012	0.000383	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	0.000117	0.000375	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	0.000116	0.000371	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HES1—brain cancer	0.000104	0.000331	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	0.000102	0.000327	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—BSG—brain cancer	0.000102	0.000326	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TP53—brain cancer	0.000102	0.000326	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—IL2—brain cancer	0.0001	0.000321	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PDGFRA—brain cancer	9.86e-05	0.000315	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SPP1—brain cancer	9.57e-05	0.000306	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	9.41e-05	0.000301	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	9.2e-05	0.000294	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL2—brain cancer	9.11e-05	0.000291	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—IDH1—brain cancer	8.77e-05	0.00028	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IRS2—brain cancer	8.66e-05	0.000277	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CG—brain cancer	8.53e-05	0.000273	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	7.73e-05	0.000247	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—APC—brain cancer	7.65e-05	0.000244	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CG—brain cancer	7.65e-05	0.000244	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—EGFR—brain cancer	6.97e-05	0.000223	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CG—brain cancer	6.93e-05	0.000222	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ENO2—brain cancer	6.93e-05	0.000222	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RELA—brain cancer	5.98e-05	0.000191	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ERBB2—brain cancer	5.94e-05	0.00019	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL2—brain cancer	5.38e-05	0.000172	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCND1—brain cancer	5.25e-05	0.000168	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CTNNB1—brain cancer	5.2e-05	0.000166	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VEGFA—brain cancer	4.57e-05	0.000146	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—STAT3—brain cancer	4.53e-05	0.000145	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MYC—brain cancer	4.21e-05	0.000134	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EGFR—brain cancer	4.12e-05	0.000132	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TP53—brain cancer	3.46e-05	0.00011	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CG—brain cancer	3.18e-05	0.000102	CbGpPWpGaD
